Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Affimed Announces Updated AFM13 Clinical Data Presentation at ASH
Heidelberg, Germany, December 7, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
Kiadis announces new data at the 2020 ASH Annual Meeting and Exposition
Amsterdam, The Netherlands, December 6, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage…
Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients
December 06, 2020 - FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) today announced updated results from the magrolimab Phase 1b trial. Mag…
Constellation Pharmaceuticals Provides Update of MANIFEST Study for CPI-0610 at ASH Meeting
CAMBRIDGE, Mass., Dec. 06, 2020 - Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced that two oral presentations and three posters rel…
Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at ASH
SAN DIEGO, Dec. 05, 2020 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medi…
New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial
December 05, 2020 - SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 tri…
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: ASH Update
BOSTON, MA, December 5, 2020 - Verastem, Inc. (Nasdaq:VSTM), a biopharmaceutical company today presented the expansion phase initial results for COPIK…
Affimed Announces Publication of Final Study Results of AFM13 in Combination with anti-PD-1 therapy in Blood
Heidelberg, Germany, November 19, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their…
Promising Preclinical Combinations of AFM13 and Natural Killer Cells Presented at SITC
Heidelberg, Germany, November 9, 2020 - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their …
News
LLS Statement on Oral Arguments in California v. Texas
This week, the Supreme Court of the United States hears oral arguments in California v. Texas, the case challenging the Affordable Care Act.
Sanofi offers to acquire Kiadis for €308 million
Paris, France and Amsterdam, The Netherlands, 2 November 2020 – Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
